{"id":"cyclosporine-placebo-cyclosporine","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-30","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the production of interleukin-2 and other cytokines essential for T-cell proliferation and immune response. The placebo-controlled formulation in this study allows for comparison of cyclosporine's immunosuppressive effects against no active treatment.","oneSentence":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:34.600Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune and inflammatory conditions (context-dependent based on trial indication)"}]},"trialDetails":[{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT04380740","phase":"PHASE2","title":"Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2022-03-30","conditions":"Graft Vs Host Disease","enrollment":160},{"nctId":"NCT07377058","phase":"NA","title":"RCT of Tocilizumab for Anti-MDA5+DM","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-11-01","conditions":"Dermatomyositis","enrollment":110},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT06334497","phase":"PHASE3","title":"Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-08-14","conditions":"Cytomegalovirus Infection","enrollment":80},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT06658002","phase":"PHASE3","title":"Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-01","conditions":"Fungal Keratitis, Corneal Ulcer","enrollment":150},{"nctId":"NCT07029204","phase":"EARLY_PHASE1","title":"Intralesional Cyclosporine for Alopecia Areata","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-08-19","conditions":"Alopecia Areata","enrollment":12},{"nctId":"NCT01502774","phase":"PHASE3","title":"Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-04","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":970},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05153070","phase":"PHASE2","title":"Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-21","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT00974142","phase":"PHASE1, PHASE2","title":"Oral Cyclosporine in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Michael Donahoe","startDate":"2009-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":43},{"nctId":"NCT02773225","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)","status":"COMPLETED","sponsor":"B. Höchsmann","startDate":"2015-01-27","conditions":"Anemia, Aplastic","enrollment":93},{"nctId":"NCT05149313","phase":"PHASE3","title":"A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2021-12-23","conditions":"Dermatitis, Atopic, Eczema","enrollment":331},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT05946772","phase":"PHASE2","title":"Cyclosporine In Takotsubo Syndrome","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2025-02-01","conditions":"Takotsubo Cardiomyopathy","enrollment":204},{"nctId":"NCT02618577","phase":"PHASE3","title":"Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes","status":"TERMINATED","sponsor":"Atrial Fibrillation Network","startDate":"2016-02","conditions":"Atrial High Rate Episodes","enrollment":2608},{"nctId":"NCT02907554","phase":"PHASE4","title":"Cyclosporine a Pretreatment and Kidney Graft Function","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2017-12-19","conditions":"Brain Death, Kidney Transplantation","enrollment":648},{"nctId":"NCT06624384","phase":"PHASE1","title":"Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024","status":"NOT_YET_RECRUITING","sponsor":"Mohsen Pourazizi","startDate":"2024-10-30","conditions":"Ocular Surface Symptom, Ocular Surface Disease, Eye Pain","enrollment":150},{"nctId":"NCT03930615","phase":"PHASE3","title":"Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-21","conditions":"Cytomegalovirus Infection","enrollment":220},{"nctId":"NCT05720715","phase":"PHASE4","title":"Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2022-01-01","conditions":"Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis","enrollment":30},{"nctId":"NCT03428100","phase":"PHASE3","title":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-05-15","conditions":"Atopic Dermatitis","enrollment":463},{"nctId":"NCT04362670","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2020-04-23","conditions":"Dry Eye Disease","enrollment":153},{"nctId":"NCT04107675","phase":"PHASE2","title":"A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)","status":"TERMINATED","sponsor":"Zambon SpA","startDate":"2020-02-11","conditions":"Bronchiolitis Obliterans Syndrome (BOS), GVHD, Chronic, Stem Cell Transplant Complications","enrollment":6},{"nctId":"NCT05056779","phase":"PHASE3","title":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable","status":"WITHDRAWN","sponsor":"Galderma R&D","startDate":"2023-01","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":""},{"nctId":"NCT05797623","phase":"PHASE2","title":"Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04-26","conditions":"Non-severe Aplastic Anemia","enrollment":78},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT03443869","phase":"PHASE3","title":"Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-05-03","conditions":"CMV Disease","enrollment":601},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT05691764","phase":"NA","title":"Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2020-09-01","conditions":"Myocardial Injury, Cardiac Surgery","enrollment":40},{"nctId":"NCT04673604","phase":"NA","title":"From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2018-05-06","conditions":"Glaucoma, Ocular Surface Disease","enrollment":42},{"nctId":"NCT01751126","phase":"PHASE3","title":"Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2013-04-29","conditions":"Vernal Keratoconjunctivitis","enrollment":169},{"nctId":"NCT03844932","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"TERMINATED","sponsor":"Sublimity Therapeutics Holdco Limited","startDate":"2019-01-24","conditions":"Colitis, Ulcerative","enrollment":235},{"nctId":"NCT04714099","phase":"PHASE3","title":"Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2015-01-01","conditions":"Dry Eye","enrollment":40},{"nctId":"NCT00983060","phase":"PHASE2","title":"Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Chronic Hepatitis C Genotype-1 Relapse","enrollment":59},{"nctId":"NCT01193660","phase":"NA","title":"Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy","status":"COMPLETED","sponsor":"Sung Kwang Medical Foundation","startDate":"2010-05","conditions":"Cerebral Palsy","enrollment":105},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT04128358","phase":"NA","title":"Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-11","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":180},{"nctId":"NCT02137772","phase":"PHASE3","title":"Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-06","conditions":"Prevention of CMV Infection or Disease","enrollment":570},{"nctId":"NCT01527240","phase":"PHASE2","title":"Neuroprotection Impact of Cyclosporin A in Cerebral Infarction","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-10","conditions":"Stroke","enrollment":126},{"nctId":"NCT02876250","phase":"PHASE3","title":"Postconditioning by Cyclosporin A in Pulmonary Transplantation","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2017-01","conditions":"Lung Transplantation","enrollment":""},{"nctId":"NCT02887807","phase":"PHASE3","title":"CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2017-01","conditions":"Shockable Out of Hospital Cardiac Arrest","enrollment":""},{"nctId":"NCT02934217","phase":"PHASE3","title":"Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-03","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":868},{"nctId":"NCT02865356","phase":"PHASE2","title":"Topical Solution for the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Spherium Biomed","startDate":"2016-09","conditions":"Atopic Dermatitis","enrollment":36},{"nctId":"NCT02917512","phase":"PHASE2","title":"Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-03","conditions":"Dry Eye Syndrome","enrollment":114},{"nctId":"NCT02390674","phase":"PHASE2","title":"Ciclosporin to Reduce Reperfusion Injury in Primary PCI","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2015-03","conditions":"Myocardial Reperfusion Injury","enrollment":54},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT02496975","phase":"PHASE1, PHASE2","title":"Traumatic Brain Injury and Effects of Acute Cyclosporine A","status":"WITHDRAWN","sponsor":"Edward Hall,PhD","startDate":"2017-08-07","conditions":"Traumatic Brain Injury","enrollment":""},{"nctId":"NCT00553735","phase":"PHASE4","title":"The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2007-08","conditions":"Dry Eye","enrollment":8},{"nctId":"NCT00755040","phase":"PHASE3","title":"Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2008-10","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":164},{"nctId":"NCT01552629","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01-05","conditions":"Atopic Dermatitis","enrollment":22},{"nctId":"NCT01072526","phase":"PHASE2","title":"Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2007-12","conditions":"Dry Eye Syndromes","enrollment":7},{"nctId":"NCT01654211","phase":"PHASE1","title":"A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07","conditions":"Healthy Volunteer","enrollment":33},{"nctId":"NCT02397213","phase":"PHASE2","title":"Ciclosporin to Protect Renal Function In Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-04","conditions":"Acute Kidney Injury","enrollment":155},{"nctId":"NCT02744872","phase":"PHASE4","title":"Copenhagen Acute Renal Complications After Transplantations Study Group","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2013-09","conditions":"Disorder Related to Lung Transplantation","enrollment":42},{"nctId":"NCT00048165","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-08","conditions":"Heart Transplantation","enrollment":434},{"nctId":"NCT00739349","phase":"PHASE2","title":"NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2008-08","conditions":"Dry Eye","enrollment":132},{"nctId":"NCT01762657","phase":"PHASE3","title":"The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Perle Bioscience, Inc.","startDate":"2014-09","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01901471","phase":"PHASE2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT02225756","phase":"PHASE2","title":"Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-12","conditions":"Abdominal Aortic Aneurysm,, Small Abdominal Aortic Aneurysm","enrollment":360},{"nctId":"NCT01334892","phase":"PHASE2, PHASE3","title":"L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients","status":"TERMINATED","sponsor":"Pari Pharma GmbH","startDate":"2009-12","conditions":"Bronchiolitis Obliterans","enrollment":130},{"nctId":"NCT00298324","phase":"PHASE3","title":"Myfortic - Treatment for Extensive cGvHD","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2006-09","conditions":"Graft vs Host Disease","enrollment":34},{"nctId":"NCT01497483","phase":"PHASE1","title":"Drug-Drug Interaction Study With Pravastatin and Cyclosporine","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-12","conditions":"Healthy","enrollment":21},{"nctId":"NCT00081055","phase":"PHASE2","title":"OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00377325","phase":"PHASE2","title":"The Effectiveness of Lower Cyclosporine Doses for Psoriasis","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2007-06","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT02291770","phase":"PHASE3","title":"Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2014-10","conditions":"Chronic Graft-Versus-Host Disease","enrollment":130},{"nctId":"NCT01002859","phase":"PHASE2","title":"Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2009-04","conditions":"Coronary Artery Bypass Surgery, Cardiopulmonary Bypass","enrollment":50},{"nctId":"NCT02113293","phase":"PHASE1","title":"CyclASol® Phase 1 Study","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2014-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00991458","phase":"PHASE2","title":"Study of Cyclosporine in Post-LASIK Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-10","conditions":"Laser In Situ Keratomileusis","enrollment":621},{"nctId":"NCT01850979","phase":"PHASE4","title":"Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-02","conditions":"Sjogren Syndrome, Dry Eye Syndrome","enrollment":24},{"nctId":"NCT00784719","phase":"PHASE1, PHASE2","title":"A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Dry Eye Syndromes","enrollment":327},{"nctId":"NCT00783107","phase":"PHASE1","title":"Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":8},{"nctId":"NCT00884585","phase":"PHASE3","title":"Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-05","conditions":"Atopic Conjunctivitis","enrollment":176},{"nctId":"NCT00447187","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk","status":"TERMINATED","sponsor":"Lux Biosciences, Inc.","startDate":"2007-04","conditions":"Corneal Diseases, Cornea Transplant","enrollment":368},{"nctId":"NCT00447642","phase":"PHASE3","title":"Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty","status":"TERMINATED","sponsor":"Lux Biosciences, Inc.","startDate":"2007-04","conditions":"Corneal Transplantation, Corneal Graft Rejection","enrollment":122},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Epiphora","enrollment":""},{"nctId":"NCT00581555","phase":"PHASE4","title":"Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-10","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT01033305","phase":"PHASE2","title":"Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)","status":"COMPLETED","sponsor":"Sigmoid Pharma","startDate":"2010-03","conditions":"Mild to Moderate Ulcerative Colitis","enrollment":118},{"nctId":"NCT01120132","phase":"PHASE2","title":"Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":716},{"nctId":"NCT00833495","phase":"PHASE2","title":"Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2009-01","conditions":"Allergic Conjunctivitis","enrollment":155},{"nctId":"NCT00766909","phase":"PHASE4","title":"Diabetogenicity of Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-03","conditions":"Complications of Transplanted Organs and Tissue, Diabetes Mellitus Nos New Onset","enrollment":18},{"nctId":"NCT00400400","phase":"PHASE4","title":"Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":400},{"nctId":"NCT00438360","phase":"PHASE3","title":"Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Chronic Plaque Psoriasis","enrollment":243},{"nctId":"NCT00990795","phase":"PHASE1","title":"Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-04","conditions":"Cardiac Surgical Procedures","enrollment":72},{"nctId":"NCT00228020","phase":"PHASE3","title":"Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-05","conditions":"Pediatric Kidney Transplantation","enrollment":212},{"nctId":"NCT01068054","phase":"PHASE2, PHASE3","title":"Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2003-06","conditions":"Keratoconjunctivitis, Vernal","enrollment":24},{"nctId":"NCT00408187","phase":"PHASE3","title":"Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2006-12","conditions":"Psoriasis","enrollment":642},{"nctId":"NCT00050661","phase":"PHASE1, PHASE2","title":"To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"1997-10","conditions":"Psoriasis","enrollment":6},{"nctId":"NCT00001965","phase":"PHASE2","title":"Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-12","conditions":"Cardiomyopathy, Hypertrophic, Heart Hypertrophy","enrollment":32},{"nctId":"NCT00209859","phase":"PHASE4","title":"Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"1998-10","conditions":"Rheumatoid Arthritis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cyclosporine/placebo-cyclosporine","genericName":"Cyclosporine/placebo-cyclosporine","companyName":"Hvidovre University Hospital","companyId":"hvidovre-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines. Used for Organ transplant rejection prevention, Autoimmune and inflammatory conditions (context-dependent based on trial indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}